Page 4 of 7 · 162 questions tagged tirzepatide.
A report I have includes traces at two wavelengths from the same injection, using a diode-array detector. The 214 nm trace integrates to 98.6% and the 280 nm trace to…
The specifics, since they change the answer: STEP 2 · survodutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would…
Concretely: SOUL · liraglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Is there data…
My weekly dose currently lands on a Thursday and that is now the worst day of my week for it. I want it on a Sunday. That is a three-day move and I can see two ways…
I noticed that the placebo arms in this literature do not behave consistently. STEP 1 placebo loses 2.4%. STEP 3 placebo loses 5.7%. SURMOUNT-3 placebo gains 2.5%.…
The case in front of me: semaglutide · semaglutide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it…
The specifics, since they change the answer: tirzepatide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists.…
I have been reading across the programmes and the A1c numbers do not line up in any way I can make sense of. SURPASS-2 reports tirzepatide lowering A1c by more than 2…
For reference: SURMOUNT-3 · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…
I am trying to specify a method to a contract lab rather than accept their default, and I do not know enough to write a sensible specification. The choices I can see…
Concretely: survodutide · liraglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…
What I have: ATTAIN-1 · dulaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…
This is my second independent submission on material from the same supplier. I would rather understand the derivation than memorise the outcome. Two people I asked…
Conditions: PIONEER-1 · liraglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs…
Stated plainly: STEP 3 · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…
Stated plainly: orforglipron · tirzepatide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
The specifics, since they change the answer: liraglutide · semaglutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read…
My background is chemistry rather than physiology, which may explain where I am stuck. This has the shape of a fact but I cannot find its origin. What I found instead…
Details up front: ESSENCE · orforglipron. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…
What I am working with: STEP 8 · cagrilintide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all citing…
Setup, so nobody has to ask: SURMOUNT-1 · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three…
The deconvolved mass spectrum on a tirzepatide report shows the expected 4813.5 peak plus three satellites I do not understand: one at 4795.5, one at 4814.5 that…
Details up front: SURPASS-2 · dulaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…
Details up front: cagrilintide · retatrutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…